Archive: 2026/03

Replicate study designs are essential for assessing bioequivalence in highly variable drugs, reducing sample sizes by up to 75% while maintaining statistical rigor. Learn how full and partial designs work, regulatory differences between FDA and EMA, and why they’re now the industry standard.